Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “I am delighted that we now have all three aspects of our human study scheduled. Data from the two initial tests is expected

SkinBiotherapeutics (LON:SBTX) CEO Catherine O’Neill presenting at the shares and AJ Bell investors evening in Edinburgh.  

First, let’s briefly talk about the microbiome. The gut microbiome refers to the trillions of bacteria that live within our gastrointestinal tracts. If you were to collectively bunch them all

Results of pre-clinical and early clinical trials conducted by investigators at the National Institutes of Health showing the effectiveness of using bacteria to treat eczema are paving the way for

Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “Demonstrating the extended stability of the cream formulation was a key step to commencing the human study. This remains on track to start

Increasing interest in the skin microbiome as a beauty concept is beginning to challenge perceptions about the role of bacteria in the skin. But what does this really mean for

Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “The progress we’ve made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies

Like your gut, your skin also has a complex system of bacteria and fungi living on its surface. “It sounds weird and scary, but it’s actually good for you,” says

If you have found your way to this story, then there is a good chance you’re feeling the itch. Dyshidrotic Eczema is a common form of eczema that can crop

Microbes on the surface of the skin help the immune system to respond to injury and heal wounds. Immunity research have historically focused on the response to pathogens and inflammation,